MaxCyte Announces Q3 Results and Operational Restructuring
I'm PortAI, I can summarize articles.
MaxCyte reported Q3 results with a revenue of $6.8 million, down 16% year-over-year, while maintaining its 2025 revenue guidance. The company announced an operational restructuring aimed at cost reduction and profitability acceleration. MaxCyte added Moonlight Bio as a new SPL client, increasing total SPL agreements to 32. Analysts rate MXCT stock as a Buy with a $9.00 price target, though Spark's AI Analyst considers it Neutral due to financial challenges. MaxCyte focuses on cell-engineering technologies for next-generation therapies, with a market cap of $156.7 million.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments